Bristol Myers Squibb and China's Hengrui Pharma have signed a licensing deal valued at up to $15.2 billion. This agreement involves a significant collaboration between the two pharmaceutical companies.

Jiangsu Hengrui Pharmaceutical, China's largest drug company, has entered into a global collaboration and licensing agreement with US pharmaceutical giant Bristol Myers Squibb (BMS) valued at up to US$15.2 billion.